| Objective: To observe the efficacy on coronary heart disease with stable angina(Pian in the chest due to stagnation of Qi and Blood stasis)in clinical application treated by Huoxinwan, and to explore the mechanism and clinical role.Methods: Adopt randomized double-blind clinical cluster approach, and 60 patients with unstable angina(stagnation of Qi and Blood stasis) met clinical criteria inclusion were randomly divided into treatment group and control group. There are 30 patients in each group, the treatment group received Huoxinwan therapy, while the control group treated with placebo. Treatment course is eight weeks, and observe one course. Observe changes in laboratory parameters before and after treatment,such as angina, stopped rate in nitroglycerin, the TCM classification score and ECG, inflammatory cytokines.Results: Treatment group compared with the control group is a significant difference in TCM symptom total score, angina extent after treatment P<0.05). Treatment group could significantly reduce the number of episodes of unstable angina and improve the clinical symptoms of traditional Chinese medicine and laboratory parameters compared with the control group, there were significant differences(p <0.05).Conclusion: Huoxinwan can significantly alleviate the number of episodes of coronary artery disease with unstable angina,and significantly improve the clinical symptoms of traditional Chinese medicine, and regulate the factors inflammatory cells secrete inflammatory, and inhibit inflammation, and the role of stabilize atherosclerotic plaques. It is a safe and effective drug in clinical treatment of coronary artery disease with unstable angina. |
PDF Full Text Request